The aim of this study is to compare the effect of medical and surgical treatment on the history of patients with Barrett esophagus (BE) and histologic evidence of low-grade dysplasia (LGD). Summary Background Data: BE is a complication of severe gastroesophageal reflux. It is considered a major risk factor for esophageal adenocarcinoma, which may develop through stages from nondysplastic metaplasia to dysplasia (LGD and high-grade dysplasia). Presently, there are no recommended therapeutic guidelines for patients with LGD. Methods: Between 1998 through 2003, 6592 patients underwent upper endoscopy; 327 of 6592 (5%) patients had BE, and 35 of 327 (10.7%) had LGD. Nineteen patients with LGD were treated with high-dose proton pump inhibitors, and 16 patients underwent laparoscopic Nissen fundoplication. Endoscopic and histologic follow-up was available in all patients after 18 months. We used multiple logistic regression to examine the effect of the 2 treatments on regression of LGD.
B arrett's esophagus (BE) is defined by the presence of intestinal metaplasia and goblet cells in biopsy from lower esophagus. BE is a complication observed in a small subset of patients with chronic gastroesophageal reflux disease (GERD), and endoscopic studies demonstrate that 5% to 15% of individuals with GERD develop BE. 1, 2 Population-based data have shown a marked increase in the incidence of esophageal adenocarcinoma in Western countries in the last decades. Adenocarcinoma of the esophagus may develop through stages from nondysplastic metaplasia to increasing grade of dysplasia (low-grade dysplasia ͓LGD͔ and high-grade dysplasia ͓HGD͔), and eventually adenocarcinoma. 3 BE represents the principal risk factor for adenocarcinoma of the esophagus 4, 5 with an estimated 30/ 125-times greater risk of developing cancer than the general population. 6, 7 Ten percent to 20% of BE patients have dysplasia at first endoscopic examination, 8 where dysplasia can be considered a step in the progression of the disease toward adenocarcinoma. At present, the guidelines proposed by the American College of Gastroenterology recommend that endoscopic surveillance with biopsies should be performed 2 times at an interval of 6 months, then yearly when LGD is detected. 9 The results of a recent randomized prospective study suggest that successful antireflux therapy may be more effective than medical therapy in respect to preventing BE from progression. 10 On the contrary, few data are available on the effect of medical or surgical treatment in the regression from LGD to intestinal metaplasia.
Presently there are no therapeutic guidelines for patients with BE and LGD. The goals of therapy for BE are the control of GERD related symptoms and maintenance of healed mucosa, 9 whereas little is known about the effect of medical versus surgical therapy in the progression or regression of dysplasia. The aim of the present study is to compare the effects of medical and surgical treatment on the natural history of patients with BE and histologic evidence of LGD.
MATERIALS AND METHODS
Between January 1998 through December 2002, 6592 patients were referred to the Department of Medical and Surgical Gastroenterology at the Azienda Ospedaliera Universitaria Pisana, Italy, to undergo upper GI endoscopy either for symptoms related to GERD or for complaints unrelated to reflux. In 327 of 6592 (5%) patients endoscopic findings suggested, and histology confirmed, the presence of Barrett's metaplasia. Forty-seven of 327 patients had histologically proven dysplasia. Of these, 5 (1.5%) patients had HGD, were considered as having carcinoma in situ, underwent esophageal resection, and were not included in the present study for data analysis. In the remaining 42 patients, histology detected LGD.
Our intent was to evaluate if there was any difference between medical and surgical therapy in respect to the natural history of the disease. Patients were allocated to medical or surgical therapy according to their own preference. Patients who were referred to the Gastrointestinal Clinic were treated with high-dose proton pump inhibitors (PPIs), whereas those referred to the Surgical Clinic underwent laparoscopic antireflux surgery (LARS).
All patients were evaluated with a detailed history before undergoing upper endoscopy, including global health status, the presence or absence of typical or atypical GERD symptoms, the predominant symptom, and the use of antiacids or PPIs.
All endoscopies were performed by 2 senior endoscopists (S.M. and A.G.), were recorded, and videos were reviewed to reduce interoperator variability. Endoscopy was performed with standard diagnostic endoscopes. BE was defined as a detectable upward displacement of the squamocolumnar junction at endoscopy, confirmed by intestinal metaplasia at histology. The esophagogastric junction was defined as the level at which the tubular esophagus joined the saccular stomach. In patients with hiatal hernia, the junction was defined by the proximal margin of gastric folds. The squamocolumnar junction was defined as the point where the normal squamous epithelium joined the red mucosa of the columnar-lined esophagus. The length of BE was measured from the esophagogastric junction to the most proximal extension of the metaplastic epithelium. Systematic 4-quadrant biopsy specimens at 2-cm intervals along the entire length of the Barrett's segment starting from the esophagogastric junction were obtained with standard-size forceps. Agreement on the presence and extension of BE mucosa and the degree of esophagitis was obtained in all cases. The esophagitis, if present, was classified into 4 grades (A-D) according to Los Angeles Classification. 11 Metaplastic columnar-lined esophagus of 3 cm or longer was defined as long-segment BE, whereas metaplasia lower than 3 cm was classified as short-segment Barrett' esophagus. All patients underwent gastric biopsies from antrum, greater curvature (2), and lesser curvature (2) for assessment of Helicobacter pylori status. Additional targeted biopsies were also taken from erosions, nodules, or ulcers.
Biopsies were fixed in formalin and included in paraffin. All biopsies were stained with hematoxylin and eosin, Alcian blue/periodic acid-Schiff, and evaluated by the same expert pathologist (Eugenio Ciancia). Histologic slices were blindly reevaluated by the same pathologist to reduce the risk of intraobserver variability. In the event of disagreement between the 2 readings, a second pathologist was involved for final diagnosis (Gabriella Marchetti).
According to Sampliner's criteria, 9 BE was classified as the presence of specialized intestinal-type metaplasia with goblet cells. Dysplasia was evaluated using the criteria of Rydell et al 12 and classified in 3 different groups: negative, indefinite, and positive. LGD and HGD represent 2 different subsets of the positive group: LGD is defined by the presence of nuclear atypia involving the mucosal surface, nuclear stratification in the base of crypts, and preserved crypt architecture; HGD is defined by the presence of marked nuclear atypia, distorted crypt architecture, and nuclear stratification extending to the luminal surface.
At the beginning of the experience, the primary antireflux procedure (laparoscopic Nissen versus Toupet fundoplication) was selected based on esophageal motility and lower esophageal sphincter pressure (the so-called "tailored approach"). Subsequently, all surgical patients underwent laparoscopic Nissen fundoplication irrespective of preoperative manometric findings, due to the high incidence of recurrent reflux and persistence of LGD (50% after Toupet fundoplication). For this reason, 7 patients who underwent Toupet fundoplication were not considered for data analysis.
The remaining 35 patients with histologically documented LGD, represent the subject of the present prospective nonrandomized study. They were divided into a medical (19 patients) and a surgical (16 patients) group according to treatment. Medical treatment consisted of hygiene, diet, and postural measures as well as high-dose PPIs (omeprazole 20 mg twice daily) for all patients. Surgical treatment, always performed by the same surgical team, consisted of laparoscopic floppy Nissen fundoplication (1.5-2 cm) over a 48-Fr bougie. Whenever present, a hiatus hernia was reduced, and the hiatus was narrowed by suturing the right and left crus posterior to the esophagus with 1 to 3 nonabsorbable sutures. The fundoplication was anchored with 2 nonabsorbable sutures to the esophagus to minimize the risk of slippage into the stomach. Any time there was difficulty in performing a tension-free wrap, enough short gastric vessels were divided to mobilize the gastric fundus.
All patients, irrespective of the treatment chosen, underwent clinical, endoscopic, and histologic assessment 6 and 18 months after treatment to evaluate the grade of dysplasia.
Demographic and clinical characteristics of patients and the effect of the 2 treatments on histology were examined separately for the 2 study groups. The Fisher exact test was used to determine if the differences between the 2 groups were statistically significant (P Ͻ 0.05).
We used multiple logistic regression to examine the association between treatment and post-treatment remission of LGD. Gender, patient's age, presence or absence of esophagitis, H. pylori infection status, presence or absence of hiatal hernia were all included as potential confounders in the multiple logistic regression model. The STATA-7 statistical package (Stata Corp., College Station, TX) was used for statistical analysis.
RESULTS
LGD was predominant in men with a male:female ratio of 1.7:1. The mean age at the time of diagnosis was 58 Ϯ 13.5 years. The reported predominant symptom is presented in Table 1 . Approximately 15% of patients reported neither any predominant symptom nor GERD-related one.
Sixty percent of patients had no endoscopic evidence of esophagitis at the time of diagnosis, while only 1 patient (2.9%) presented grade D esophagitis. Details of endoscopic findings regarding esophagitis, length of BE, and type of hiatal hernia are summarized in Table 2 . H. pylori infection was diagnosed in 6 of 35 (17.1%) patients. The 2 groups were homogeneous for demographic and pathologic (endoscopic and histologic) characteristics (Table 3 ).
Medical Group
No side effects were observed after short-and longterm medical treatment. A regression of LGD to Barrett's intestinal metaplasia was observed in 12 of 19 (63.2%) patients at endoscopic biopsies performed 12 months after treatment. A second sampling performed 6 months later confirmed the regression in the 12 patients.
Surgical Group
In this group, there were no deaths related to the operation. Postoperative complications (primarily dysphagia and gas-bloat syndrome) were rare and transient. In the surgical treatment group, 15 of 16 (93.8%) patients had complete, histologically proven, regression of dysplasia to Barrett's metaplasia 12 months after treatment. At 18 months, the absence of LGD was confirmed in the 15 patients and was observed a further regression in the other patient (100% regression rate after Nissen fundoplication). At Fisher exact test laparoscopic Nissen fundoplication was associated with a significantly higher probability of regression from LGD to Barrett's metaplasia when compared with the medical treatment (P ϭ 0.047).
The association between treatment and remission of LGD was examined using multiple logistic regression. Gender, patient age, presence or absence of esophagitis, H. pylori infection status, size of hiatal hernia, and extension of Barrett's metaplasia were included as potential confounders in the multiple logistic regression model shown in Table 4 . Controlling for the aforementioned confounders, no factors other than laparoscopic Nissen fundoplication were significantly associated with the probability of remission of LGD. On the other hand, patients who underwent the Nissen procedure had a significantly higher probability than those who underwent medical treatment of histologic proven regression of LGD at 12 to 18 months (odds ratio (OR) ϭ 15.53, P ϭ 0.033). 
DISCUSSION
To the best of our knowledge, the present paper represents the largest reported comparison study of the outcome of LGD in patients with BE treated either with medical therapy or with the Nissen antireflux procedure. At multivariate analysis, patients who underwent the Nissen fundoplication had a 16 times higher probability of histologic proven regression of LGD at 12 to 18 months than those who underwent medical therapy. We are aware that this is not randomized study and that the randomization would have increased the value of our results. Nevertheless, we think that the results of this study remain valid since with the use of multivariate analysis we had opportunity to control for many potential confounders, making the 2 groups more homogeneous for data analysis.
The ideal treatment in patients with BE should aim to obtain a complete regression of this precancerous condition. Initial studies with PPI therapy reported promising results showing a partial regression of Barrett's epithelium 13 or a partial reepithelialization in the form of squamous islands in the context of columnar-lined epithelium. 14 More recent studies demonstrated that biopsy specimens taken from such islands would often show persistent underlying intestinal metaplasia. 15 On the other hand, Gursky et al, 16 Oelschlager et al, 17 and others have obtained histologic regression of Barrett's epithelium in approximately one third of patients after successful anti reflux surgery. To date, neither medical nor surgical treatment seems to guarantee histologic regression of Barrett's metaplasia. We agree with those authors who consider this aim elusive 10 and therefore recommend endoscopic surveillance, whatever the treatment of choice.
Since patients with BE who will never develop dysplasia have no different life expectancy than patients with GERD, detection of LGD should become the current aim of surveillance. With this perspective in mind, regression from LGD to intestinal metaplasia may be the major target of therapy. Scanty data 10, 17 already reported a complete regression from LGD to Barrett's metaplasia after successful antireflux surgery. The results of our study confirm these findings and suggest that the control of acid and bilio-pancreatic refluxate may be at the origin of the regression of dysplastic tissue transformation, and strongly suggests the pathophysiologic role of combined reflux in the etiology of dysplasia. Someone could argue that this high rate of elimination of LGD could be a consequence of the definition of regression used. We believe this is not the case, since histologic slices were blindly reevaluated by the same pathologist to reduce the risk of intraobserver variability, and, in the event of disagreement between the 2 readings, a second pathologist was involved for final diagnosis. Furthermore, it should be emphasized that each patients was defined as LGD-free only after 2 consecutive biopsy controls confirmed the absence of LGD.
At present, it is impossible to predict if a patient with GERD will ever develop metaplasia and eventually dysplasia, perhaps because the mechanism leading esophageal squamous epithelium to columnar metaplasia or dysplasia is poorly understood. Furthermore, the progression of dysplasia from low to high grade and ultimately to cancer proves to be highly variable from one patient to another. There are limited data in the literature reporting on the natural history of LGD and correlating this histologic finding with clinical outcome. In a preliminary study, Weston et al reported, only in abstract form, the progressing of LGD to HGD or cancer during a 22to 41-month follow-up in 8% of patients and regressing to BE without dysplasia in 75% of patients. 18 Conversely, in a cohort study, Sontag et al demonstrated that most patients with BE and LGD (94%) continued to have dysplasia on subsequent surveillance biopsies. 19 In the aforementioned studies, it is unknown how many pathologists were involved in reading the biopsies and if existed an interobserver agreement. These 2 factors could explain the presence of such discordant results. Indeed, studying a large number of patients with BE and LGD, Richter confirmed that, when a total agreement between 3 pathologists was present in regard of LGD, progression to HGD or cancer was present in 80% of patients. 20 This result strongly suggests that when diagnosis of LGD is confirmed, its natural history is the progression toward cancer.
Recently, Sharma et al 21 and Gurski et al 16 have published 2 interesting papers on the effect of different treatments on the natural history of LGD. In the former, the author defines the outcome of patients with LGD, reporting 42% of regression to nondysplastic intestinal metaplasia after at least 1 year of follow-up, with an incidence of cancer of 0.6% for year, in accordance with the 0.2% to 1.9% reported in the literature 22 In the latter, the group of DeMeester reports regression from low-grade dysplastic to nondysplastic BE in In this study, the authors proved that, although not statistically significant, successful antireflux surgery is more efficient than medical treatment in determining regression from LGD to nondysplastic epithelium. In agreement with these results, our study shows that successful laparoscopic Nissen fundoplication is associated with a significantly increased probability of regression from LGD to nondysplastic epithelium. Our study represents one of the most numerous case series from a single institution and, although nonrandomized, it can make some light on this controversial issue. At multiple logistic regression, we showed that regression of intestinal metaplasia is 16 times more likely to occur after successful antireflux surgery when compared with high-dose PPI therapy. In our study, with the exception of the treatment chosen, no other factors (ie, age, gender, esophagitis, hiatal hernia, H. pylori infection, extension of BE metaplasia) were significantly associated with regression of LGD. This finding contrasts with previously reported data in which the extension of BE (shortsegment Barrett esophagus versus long-segment BE) correlated with the regression of metaplasia. Our findings suggest that LGD is not dependent on the extension of the disease, can be a reversible phenomenon, and the protective effect of surgery may be explained with the complete control of both acid and bile refluxate, after successful antireflux surgery.
A relative limitation of this study is represented by the relatively short follow-up. Csendes et al reviewed their experience and other 15 studies dealing with surgical treatment of BE and eventual regression or appearance of dysplasia or carcinoma at late follow-up. 23 The authors concluded that antireflux surgery could decrease but not eliminate the possibility of dysplasia or cancer. Furthermore, they showed that the longer the follow-up, the greater the possibility of progression. This finding can be explained by the loss of efficacy of the lower esophageal sphincter competence in some patients and the recurrence of the injuring refluxate. We agree that the efficacy of the antireflux mechanism may wane over time, but at the same time successful antireflux surgery puts our patients from a moderate to a mild risk of developing cancer. Therefore, in all the patients that present a regression from LGD to intestinal metaplasia, we think that we can safely offer a 5-year surveillance endoscopy. 24 Finally, some authors recommend performing at least 2 endoscopies with biopsies to confirm the diagnosis of LGD. The reason of this approach is twofold: 1) sampling errors may determine underestimation of LGD and 2) the presence of esophagitis may determine overestimation of dysplasia. We think that our protocol with 4-quadrant biopsy specimens at 2-cm intervals along the entire length of the Barrett's epithelium, the absence of esophagitis in 60% of patients at first endoscopy, and the reduction of interobserver variability with agreement between 2 pathologists give our study a correct incidence of LGD after the first endoscopy. Indeed, in our experience, we have observed a cumulative prevalence and incidence of LGD (approximately 15%) similar to that of other major observational database. 21 
CONCLUSION
The results of our study demonstrate a protective role of successful antireflux surgery when compared with medical therapy in the progression of LGD toward HGD or cancer, perhaps because by means of recreating the antireflux mechanism, surgical treatment is able only to control acid and biliopancreatic refluxate. As a consequence of these results, we recommend antireflux surgery as the treatment of choice in all patients with LGD, although at the present time there is not enough evidence to consider the presence of Barrett's metaplasia a primary indication for antireflux surgery. The complexity of assessment and management of Barrett esophagus require a multidisciplinary approach, in regard of diagnosis and strategies of treatment. This is particularly true for surgical therapy, which has to be effective and long lasting; therefore, it should be preferably performed by experienced surgical teams.
